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A B S T R AC T
Background. The incidence of left ventricular hypertrophy (LVH) in primary aldosteronism (PA) is higher than in essential hypertension. LVH is an independent cardiovascular risk factor. Treatment of PA with mineralocorticoid receptor blockers (MRBs) improves LVH. Previous studies included relatively small groups, low incidence of LVH and used high MRB dose. We tested the hypothesis that long-term regression of LVH in PA/low-renin hypertension may be achieved with low-dose MRB. Methods. Forty-eight patients (male/female 28/20, age 61.4 years, range 47-84) had PA (low renin, high aldosterone and high aldosterone/renin ratio, n = 24) or low-renin hypertension (low renin, normal aldosterone and high aldosterone/ renin ratio, n = 24). All had either LVH or concentric remodelling. All had an echocardiogram both at baseline and at 1 year after the initiation of spironolactone. A subgroup of 29 patients had an echocardiogram at baseline, 1 year (range 0.5-1.5) and 3 years (range 1.8-7). Results. At baseline, spironolactone was commenced in all patients. The dose was 33.3 ± 13.7 and 29.0 ± 11.7 mg/day at 1 year and 3 years, respectively. A total of 73% of the patients received ≤37.5 mg/day. Introduction of spironolactone enabled the reduction of other antihypertensive medications (from 2.6 ± 1.2 to 1.5 ± 1.0 at 1 year). At 1 year, systolic and diastolic blood pressure decreased (149.3 ± 14.1 to 126.2 ± 12.0 mmHg, P < 0.001, and 88.2 ± 9.8 to 78.3 ± 7.1 mmHg, P < 0.001, respectively). At baseline, LVH was present in 39 of the 48 (81%) patients, and concentric remodelling, i.e. increased relative wall thickness (RWT) with a normal left ventricular mass index (LVMI), in 36 (75%). At 1 year, LVMI decreased in 44 of the 48 (92%) patients (142.9 ± 25.4 versus 117.7 ± 20.4 g/m 2 , P < 0.001). LVH normalized in 16 of the 39 (41%) patients. RWT normalized in 36% of the patients. The changes in blood pressure and LVMI did not correlate. At 3 years, LVH decreased further and normalized in 57% of the patients. Conclusions. In patients with PA/low-renin hypertension, long-term regression of LVH may be achieved with low-dose MRB.
I N T R O D U C T I O N
The incidence of primary aldosteronism (PA) among patients with hypertension exceeds 10% [1] and may reach 20% in patients with resistant hypertension [2] . PA is associated with significantly higher cardiovascular morbidity, including left ventricular hypertrophy (LVH), atrial fibrillation, myocardial infarction and stroke, than with essential hypertension (EH) [3] [4] [5] [6] [7] [8] [9] . LVH, in particular, is more common in PA or low-renin hypertension when compared with EH or renovascular hypertension [4] [5] [6] [7] [8] [9] . LVH is an independent risk factor for cardiovascular mortality [10] . Treatment of PA with spironolactone or surgery reduces cardiovascular events [11] . Therefore, the diagnosis of PA is important as it may lead to a directed and optimal treatment of hypertension and its complications, LVH in particular. Animal studies have shown the prevention of myocardial fibrosis in primary and secondary hypertension using mineralocorticoid antagonists [12] [13] [14] . Previous studies in humans showed the improvement of left ventricular mass (LVM) in patients with PA treated by either mineralocorticoid receptor blockers (MRBs) or adrenalectomy [15] [16] [17] [18] [19] [20] . However, most of the studies included a relatively small number of patients, patients also with normal LVM and used relatively high MRB doses [15, 16, 18] .
The aim of the present study was to verify the hypothesis that, in patients with PA or with low-renin hypertension, a long-term regression of LVH may be achieved with low-dose MRB.
M AT E R I A L S A N D M E T H O D S
This is a retrospective study including patients with hypertension due to PA or low renin with high aldostrerone-renin ratio (ARR). The study was approved by the Rabin Medical Center's institutional review board. Informed consent was not required. Patient data were collected from mid-1998 through December 2011.
The criteria for PA were plasma renin activity (PRA) ≤0.5 ng/mL/h with high plasma aldosterone (≥440 pmol/L) and ARR ≥830 for patients off angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB); or PRA ≤1 ng/mL/h and ARR ≥830 for patients on either ACEi or ARB. The criteria for low-renin hypertension were PRA ≤0.5 ng/mL/min with normal plasma aldosterone and ARR ≥830 for patients not on ACEi or ARB. PRA and aldosterone were taken in the morning after 30 min of rest in a sitting position. Serum potassium was taken at the same time. All patients had either concentric LVH or concentric remodelling at their baseline echocardiography, and at least one available follow-up echocardiogram after the initiation of MRB. All echocardiograms were performed using standard machines (Philips IE33 and Philips HD11XE). Left ventricular dimensions were measured according to the recommendations of the American Society of Echocardiography [21] . For each patient, the baseline and follow-up echocardiograms were performed in the same echocardiography laboratory. LVM was calculated according to Devereux and Reichek (Penn convention):
where LVEDD is the left ventricular end-diastolic diameter, IVS, inter-ventricular septum thickness and PW, posterior wall thickness [22] . LVM was normalized to the body surface area to give a left ventricular mass index (LVMI). LVH was defined as LVMI >134 and >110 g/m 2 for males and females, respectively [23] . Relative wall thickness (RWT) was calculated as 2 × PW/LVEDD. Concentric remodelling was defined as RWT >0.44 in the presence of normal LVMI [24] . Patients were excluded if they had regional wall motion abnormality, left ventricular systolic dysfunction, significant valvular disease, anaemia or significant renal failure (estimated glomerular filtration rate [eGFR] <40 mL/min/1.73 m 2 using the chronic kidney disease epidemiology collaboration [CKD-EPI] equation [25] ). All patients had spironolactone added to their antihypertensive medications after baseline echocardiogram. Initial daily dose was 12.5-25 mg. Analysis of the clinical and echocardiographic data was performed for the whole group after 1 year of treatment with spironolactone, and for a subgroup of the patients also at 3 years (range 1.8-7 years).
Statistical analysis was done using SPSS version 17.0. Results are presented as mean ± SD for normally distributed data or median (25th-75th percentile) for non-normally distributed data. Data within the group examined at baseline and 1 year were analysed using the paired t-test, and data between groups were examined using the unpaired t-test. Data for the group examined at baseline and 1 year were analysed using the paired t-test. Data for the subgroup examined at three time periods were analysed using analysis of variance (ANOVA) with repeated measurements with Bonferroni correction. A Pvalue <0.05 was considered significant. Spearman's correlation was performed between the relevant variables.
R E S U LT S
Sixty-seven patients were screened. All had low renin and either LVH or concentric remodelling before the initiation of MRB. Fifty-nine of these patients had an echocardiogram both at baseline and 1-year follow-up. Eleven were excluded since their ARR was below the required cut-off, leaving 48 patients to be included in the final analysis. This cohort included 24 patients with PA and 24 with low-renin hypertension. There were 28 males and 20 females, and the mean age was 61.4 (range 47-84 years). Demographics and baseline data of the study group are presented in Table 1 . Except for plasma aldosterone levels (576 ± 174 versus 280 ± 75 pmol/L, P < 0.001), and ARR (3626 ± 743 versus 1821 ± 218, P = 0.024), there was no difference between patients with PA and those with lowrenin hypertension with respect to all parameters detailed in Table 1 . History of hypertension was 11.4 ± 9.6 years; and 38% were obese (body mass index ≥30 kg/m 2 ). Most of the patients were normokalemic, with serum K + = 4.2 ± 0.7 meq/L and with serum K + ≤3.6 meq/L in 7 of the 48 patients. The average number of blood pressure medications was 2.6 ± 1.2, with ACEi/ARB, calcium channel blockers, β-blockers and thiazide diuretics being the medications most commonly used (Table 1) . Seven patients had an adrenal adenoma. Their serum potassium did not differ from the rest of the group (3.9 ± 0.4 versus 4.1 ± 0.4 meq/L, P = 0.2).
As required by the inclusion criteria, all patients had either LVH or concentric remodelling with good systolic function. LVH was present in 39 (81%) patients, concentric remodelling (increased RWT with a normal LVMI) was present in 36 (75%) and an increase of both LVMI and RWT was present in 28 (58%). A follow-up echocardiogram was performed at 1.1 ± 0.2 years after the initiation of MRB (Table 2) . Systolic, diastolic and mean blood pressure all decreased significantly. All parameters of LVM including LVEDD, IVS and PW significantly decreased. The LVMI decreased in 44 (92%) patients at 1 year by 15 ± 11%. LVMI normalized in 41% of the patients, and RWT (concentric remodelling) normalized in 36% of the patients. Left atrial diameter and area decreased, as did aortic root diameter. The change in aortic root diameter correlated with the change in IVS (n = 28, r = 0.431, P = 0.022). The number of antihypertensive medications (excluding MRB) decreased from 2.6 ± 1.2 to 1.5 ± 1.0. Forty-six patients received spironolactone and two received eplerenone. Dose equivalence was calculated as 37.5 mg spironolactone = 50 mg eplerenone. The average daily dose of MRB was low at (Table 2) . Five patients experienced mastalgia and/or gynaecomastia from spironolactone, which responded to temporary discontinuation of the drug and renewal at a lower dose. One was switched to eplerenone due to painful gynaecomastia.
There was no correlation between the decrease in blood pressure from baseline to 1 year and the decrease in LVMI from baseline to 1 year (r = −0.15, P = ns for systolic blood pressure; r = −0.03, P = ns for diastolic blood pressure; r = −0.01, P = ns for mean blood pressure, respectively). There was no difference between patients with PA and those with low-renin hypertension with respect to baseline and follow-up blood pressure and echocardiographic data. At 1 year of spironolactone treatment, eGFR by CKD-EPI equation [24] decreased from 72.7 ± 18.8 to 68.6 ± 18.2 mL/min/1.73 m 2 (P = 0.034), and albumin/creatinine ratio decreased from 41.6 ± 17.3 to 10.7 ± 12.1 µg/mg (P = 0.012).
Twenty-nine patients had echocardiographic data at baseline (before MRB), at 1 year of MRB treatment and at 2 and above years of MRB treatment (mean 3.0 ± 1.0, range 1.8-7 years). Their data are presented in Table 3 and Figure 1 . At 3.0 ± 1.0 years (range 1.8-7.0), blood pressure continued to fall. The LVMI decreased further at ≥2 years in 18 of 29 patients (−13 ± 13% at 1 year, −20 ± 16% at ≥2 years, P = 0.02, Table 3 and Figure 1 ). This improvement in LVMI at ≥2 years was accounted for by improvement in IVS and PW more than in LVEDD. Left atrial area continued to decrease at ≥2 years. The number of antihypertensive medications decreased after 1 year of spironolactone and remained so at 2 and above years. The average MRB dose decreased to 29.0 ± 11.7 mg/day (Table 3) .
Four patients discontinued spironolactone for an average period of 3.6 (range 2.7-5 years). During that time, all had worsening of LVH, which improved upon resuming MRB at a daily dose of 25 ± 10.2 mg (spironolactone in three patients and eplerenone in one, Table 4 ). After resuming MRB, LVMI decreased from 139.5 ± 19.3 to 113.3 ± 13.4 g/m 2 (P = 0.005) during the follow-up period of 1.75 (range 1-3 years; Table 4 ).
D I S C U S S I O N
The incidence of hyperaldosteronism has increased since the application of the ARR as a screening test. LVH is more common in PA than in EH [9] , and it is known that LVH is an independent cardiovascular risk factor [10] . Improvement in LVH in EH was associated with reduced cardiovascular mortality and morbidity [26] . Treatment of PA with spironolactone or surgery reduced and equalized the incidence of cardiovascular events to that of EH [11] . Thus, it seems reasonable to search for PA among patients with hypertension, since treating these patients with MRBs may lead to a better control of blood pressure and target organ damage with fewer medications. The partial or complete reversal of LVH has been reported in a few studies in humans with PA. However, the numbers of patients were small, the follow-up was short in most studies and the MRB dose used in some of the studies 
O R I G I N A L A R T I C L E
was high. Furthermore, LVH was not required for inclusion. Rossi et al. [16] reported improvement of LVMI in 34 patients with PA after therapy. However, only 50% had LVH at baseline. At 1 year, 25 patients were available for follow-up, with only six on medical therapy and the majority after adrenalectomy [16] . Lin et al. [20] reported the reversal of LVH 6 months after adrenalectomy in 12 of the 20 patients. LVH was not an inclusion criterion and was present in only 60% of the patients at baseline. Gaddam et al. [18] reported the improvement of LVH by cardiac magnetic resonance imaging in 19 patients with PA after 6 months of combination antihypertensive agents, which also included 50 mg spironolactone. Pringle et al. [17] reported the improvement of LVH by electrocardiogram in 34 patients with PA, 17 after adrenalectomy, 9 after medical therapy and 8 with combined medical and surgical treatments. A comprehensive and prospective study was reported by Catena et al. [15] . Fifty-four patients with PA were followed for 1-6.4 years following either adrenalectomy or spironolactone therapy. After 1 year, the reversal of LVH was shown only in the adrenalectomy subgroup, while at 7 years, reversal of LVH was comparable between adrenalectomy and spironolactone. In that study also, LVH was not required for inclusion, and its incidence was 36%. The daily dose of spironolactone was high at 120 (50-300 mg), which may lead to side effects necessitating stoppage of the drugs. This current study included 48 patients, all of which had LVH or increased RWT at baseline. At 1 year after spironolactone commencement, LVH improved in 92% of the patients, and the complete reversal of LVH to normal values was impressive, occurring in 41%. This was achieved at a small daily dose of spironolactone, with 73% of the patients receiving ≤37.5 mg. A further improvement in LVH was observed after 
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3 (range 1.8-7 years), with normalization of LVH in ∼60% of the patients. There was no difference in all baseline and follow-up echocardiographic parameters between the patients with PA and those with low-renin hypertension (who by definition had inappropriately high aldosterone levels), which qualified their inclusion in one group. Although blood pressure decreased with spironolactone, there was no correlation between the change in BP and the change in LVMI. This may suggest that the reversal of LVH by spironolactone is independent of its hypotensive effect. This has been supported by data from studies in both animals [14, 27] and humans [28, 29] . In patients with EH, adding a small dose of spironolactone to ACEi led to the reversal of LVH and diastolic dysfunction, both independent of blood pressure [28, 29] . These studies put emphasis on the fact that the non-epithelial effects of mineralocorticoid blockers, such as their effect on myocardial remodelling, may be achieved with small doses in situations of aldosterone escape, such as in EH treated with ACEi, or in congestive heart failure [30, 31] . The findings in this current study concur with this approach and prove that, even in PA, small doses of MRBs are sufficient for the regression of LVH. Mineralocorticoid receptor blockers act through local receptors in the heart and reduce perivascular inflammation and myocardial fibrosis in both animal models and humans [12, 13, 26, [32] [33] [34] .
It is noteworthy that all components of LVM improved, including reduction in LVEDD, IVS and PW. The decrease in LVEDD may be attributed to the volume reduction related to the diuretic effect of spironolactone [18] , or to the increased excretion of atrial natriuretic peptide or other natriuretic substances associated with high aldosterone [35, 36] . Thus, the effect of spironolactone relieved both pressure overload (concentric hypertrophy and concentric remodelling) and volume overload (by decreasing LVEDD). This, as mentioned above, Table 3 . Blood pressure and echocardiographical data before and after MRB in patients with PA (ANOVA with Bonferroni correction, n = 29) was achieved either by lowering blood pressure, or by a direct independent effect on the heart. The study limitations are (i) the study is retrospective with the lack of a control group with EH. Yet, in this relatively large group of patients with PA, where each patient served as his own control, the long-term effect of MRB on LVH regression was prominent and unequivocal. (ii) Data regarding salt intake at each time point are not present. LVH as well as other target organ damage induced by aldosterone is dependent on salt intake [27, 34] .
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